Table 1 Baseline demographic and clinical characteristics—comparison between the two study groups (2866 participants)
From: HbA1C variability among type 2 diabetic patients: a retrospective cohort study
Variable | HbA1C variability (N = 632) | No HbA1C variability (N = 2234) | p value |
|---|---|---|---|
Gender | |||
Male: (N = 1242) | 43.4% (274) | 43.3% (968) | 0.991 |
Female: (N = 1624) | 56.6% (358) | 56.7% (1266) | |
Country of origin | |||
Israel: (N = 910) | 44.7% (281) | 28.2% (629) | < 0.001 |
USA and Western Europe: (N = 26) | 0.3% (2) | 1.1% (24) | |
Russia and Eastern Europe: (N = 585) | 16.4% (103) | 21.6% (482) | |
Asia and Africa: (N = 1285) | 37.4% (235) | 47.1% (1050) | |
South America: (N = 49) | 1.1% (7) | 1.9% (42) | |
Age (beginning of study) | 55.6 ± 7.8 | 59.5 ± 7.2 | < 0.001 |
Smokers: (N = 895) | 37.1% (228) | 31.3% (667) | 0.007 |
Ischemic heart disease diagnosis: (N = 903) | 36.2% (222) | 32.0% (681) | 0.052 |
Obesity BMI ≥ 30: (N = 1274) | 49.0% (308) | 43.7% (966) | 0.018 |
Hyperlipidemia diagnosis in medical records (N = 2235) | 78.3% (495) | 77.9% (1740) | 0.816 |
Hypertension diagnosis in medical records (N = 1827) | 61.6% (386) | 64.5% (1441) | 0.114 |
Visits at Diabetic clinic: (N = 693) | 28.6% (181) | 22.9% (512) | 0.003 |
HbA1C counts during study period | 20.5 ± 6.8 | 21.09 ± 6.8 | 0.057 |